A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
Open accessAbstract
PCSK9 binds to the low density lipoprotein receptor (LDLR) and leads to LDLR degradation and inhibition of plasma LDL cholesterol clearance. Consequently, the role of PCSK9 in modulating circulating LDL makes it a promising therapeutic target for treating hypercholesterolemia and coronary heart disease. Although the C-terminal domain of PCSK9 is not involved in LDLR binding, the location of several naturally occurring mutations within this region suggests that it has an important role for PCSK9 function. Using a phage display library, we identified an anti-PCSK9 Fab (fragment antigen binding), 1G08, with subnanomolar affinity for PCSK9. In an assay measuring LDL uptake in HEK293 and HepG2 cells, 1G08 Fab reduced 50% the PCSK9-dependent inhibitory effects on LDL uptake. Importantly, we found that 1G08 did not affect the PCSK9-LDLR interaction but inhibited the internalization of PCSK9 in these cells. Furthermore, proteolysis and site-directed mutagenesis studies demonstrated that 1G08 Fab binds a region of beta-strands encompassing Arg-549, Arg-580, Arg-582, Glu-607, Lys-609, and Glu-612 in the PCSK9 C-terminal domain. Consistent with these results, 1G08 fails to bind PCSK9DeltaC, a truncated form of PCSK9 lacking the C-terminal domain. Additional studies revealed that lack of the C-terminal domain compromised the ability of PCSK9 to internalize into cells, and to inhibit LDL uptake. Together, the present study demonstrate that the PCSK9 C-terminal domain contribute to its inhibition of LDLR function mainly through its role in the cellular uptake of PCSK9 and LDLR complex. 1G08 Fab represents a useful new tool for delineating the mechanism of PCSK9 uptake and LDLR degradation.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A cohort study has revealed secondary-prevention effects of probucol in patients with heterozygous FH.
“Moreover, a cohort study has also revealed secondary-prevention effects of probucol in patients with heterozygous FH679).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [679]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Sequence Variations in <i>PCSK9,</i> Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · see citing works
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985 · see citing works
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · see citing works
Common variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364 · see citing works
Myocardial Infarction Genetics Consortium (2009) · Nature Genetics · doi:10.1038/ng.327 · Cited by 1,088 · see citing works
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681 · see citing works
Frank-Kamenetsky, M. D., Grefhorst, A., Anderson, N. N., Racie, T., Bramlage, B., Akinc, A., Butler, D., Charissé, K., Dorkin, J. R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 635 · see citing works
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517 · see citing works
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., et al. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1235 · Cited by 430 · see citing works
Molecular basis for LDL receptor recognition by PCSK9
Kwon, H. J., Lagace, T. A., McNutt, M., Horton, J. D., & Deisenhofer, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712064105 · Cited by 418 · see citing works
Chan, J. C. Y., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J. T., Liu, Q., Higbee, J., Xia, Z., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903849106 · Cited by 410 · see citing works
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
Timms, K. M., Wagner, S., Samuels, M. E., Forbey, K. C., Goldfine, H., Jammulapati, S., Skolnick, M. H., Hopkins, P. N., Hunt, S. C., & Shattuck, D. (2004) · Human Genetics · doi:10.1007/s00439-003-1071-9 · Cited by 322 · see citing works
Abifadel, M., Rabès, J., Devillers, M., Münnich, A., Erlich, D., Junien, C., Varret, M., & Boileau, C. (2009) · Human Mutation · doi:10.1002/humu.20882 · Cited by 255 · see citing works
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Piper, D. E., Jackson, S., Liu, Q., Romanow, W. G., Shetterly, S., Thibault, S. T., Shan, B., & Walker, N. P. C. (2007) · Structure · doi:10.1016/j.str.2007.04.004 · Cited by 251 · see citing works
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nassoury, N., Blasiole, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., & Seidah, N. G. (2007) · Traffic · doi:10.1111/j.1600-0854.2007.00562.x · Cited by 248 · see citing works
Rothe, C., Urlinger, S., Löhning, C., Prassler, J., Stark, Y., Jäger, U., Hubner, B., Bardroff, M., Pradel, I., Boß, M., et al. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.12.018 · Cited by 248 · see citing works
Berge, K. E., Ose, L., & Leren, T. P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000204337.81286.1c · Cited by 236 · see citing works
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
Zhang, D., Garuti, R., Tang, W.-J., Cohen, J. C., & Hobbs, H. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806312105 · Cited by 235 · see citing works
Plasma PCSK9 preferentially reduces liver LDL receptors in mice
Grefhorst, A., McNutt, M., Lagace, T. A., & Horton, J. D. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800027-jlr200 · Cited by 203 · see citing works
Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation
Fisher, T. S., Surdo, P. L., Pandit, S., Mattu, M., Santoro, J. C., Wisniewski, D., Cummings, R. T., Calzetta, A., Cubbon, R. M., Fischer, P. A., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701634200 · Cited by 196 · see citing works
Self-citationPCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
Shan, L., Pang, L., Zhang, R., Murgolo, N. J., Lan, H., & Hedrick, J. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.106 · Cited by 180 · see citing works
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
McNutt, M., Kwon, H. J., Chen, C., Chen, J. R., Horton, J. D., & Lagace, T. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808802200 · Cited by 155 · see citing works
Mayer, G., Poirier, S., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805971200 · Cited by 154 · see citing works
Hampton, E. N., Knuth, M. W., Li, J., Harris, J. L., Lesley, S. A., & Spraggon, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703402104 · Cited by 148 · see citing works
Bottomley, M. J., Cirillo, A., Orsatti, L., Ruggeri, L., Fisher, T. S., Santoro, J. C., Cummings, R. T., Cubbon, R. M., Surdo, P. L., Calzetta, A., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m808363200 · Cited by 133 · see citing works
Self-citationRauchenberger, R., Borges, E., Thomassen-Wolf, E., Rom, E., Adar, R., Yaniv, Y., Malka, M., Chumakov, I., Kotzer, S., Resnitzky, D., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303164200 · Cited by 127 · see citing works
Schmidt, R. J., Beyer, T. P., Bensch, W. R., Qian, Y., Lin, A., Kowala, M. C., Alborn, W. E., Konrad, R. J., & Cao, G. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.004 · Cited by 102 · see citing works
Duff, C. J., Scott, M. J., Kirby, I. T., Hutchinson, S. E., Martin, S. L., & Hooper, N. M. (2009) · Biochemical Journal · doi:10.1042/bj20082407 · Cited by 99 · see citing works
PCSK9 and LDL cholesterol: unravelling the target to design the bullet
Costet, P., Krempf, M., & Cariou, B. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.06.005 · Cited by 87 · see citing works
WT PCSK9-DELTAC BOUND TO WT EGF-A OF LDLR
Bottomley, M. J., Cirillo, A. A., Orsatti, L., Ruggeri, L., Fisher, T. S., Santoro, J. C., Cummings, R. T., Cubbon, R. M., Surdo, P. L., Calzetta, A., et al. (2008) · Worldwide Protein Data Bank · doi:10.2210/pdb2w2m/pdb · Cited by 70 · see citing works
Self-citationFunctional analysis of sites within PCSK9 responsible for hypercholesterolemia
Pandit, S., Wisniewski, D., Santoro, J. C., Ha, S., Ramakrishnan, V., Cubbon, R. M., Cummings, R. T., Wright, S. D., Sparrow, C. P., Sitlani, A., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800049-jlr200 · Cited by 49 · see citing works
Self-citationCameron, J., Holla, Ø. L., Laerdahl, J. K., Kulseth, M. A., Berge, K. E., & Leren, T. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.10.007 · Cited by 29 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- Zhang, D. W., Garuti, R., Tang, W. J., Cohen, J. C., and Hobbs, H. H. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 13045-13050
- Chan, J. C., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., Di, Y., Shetterly, S., Arimura, Z., Salomonis, H., Romanow, W. G., Thibault, S. T., Zhang, R., Cao, P., Yang, X. P., Yu, T., Lu, M., Retter, M. W., Kwon, G., Henne, K., Pan, O., Tsai, M. M., Fuchslocher, B., Yang, E., Zhou, L., Lee, K. J., Daris, M., Sheng, J., Wang, Y., Shen, W. D., Yeh, W. C., Emery, M., Walker, N. P., Shan, B., Schwarz, M., and Jackson, S. M. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 9820 -9825
- Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., Gamba-Vitalo, C., Hadwiger, P., Jayaraman, M., John, M., Jayaprakash, K. N., Maier, M., Nechev, L., Rajeev, K. G., Read, T., Ro ¨hl, I., Soutschek, J., Tan, P., Wong, J., Wang, G., Zimmermann, T., de Fougerolles, A., Vornlocher, H. P., Langer, R., Anderson, D. G., Manoharan, M., Koteliansky, V., Horton, J. D., and Fitzgerald, K. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 11915-11920
- Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., and Deisenhofer, J. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 1820 -1825
- Hampton, E. N., Knuth, M. W., Li, J., Harris, J. L., Lesley, S. A., and Sprag- gon, G. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 14604 -14609
Cited by
Sorted by citations
The biology and therapeutic targeting of the proprotein convertases
Seidah, N. G., & Prat, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3699 · Cited by 819 · see citing works
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813 · see citing works
Lambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448 · see citing works
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 317 · see citing works
Welder, G. J., Zineh, I., Pacanowski, M. A., Troutt, J. S., Cao, G., & Konrad, R. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m008144 · Cited by 250 · see citing works
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Surdo, P. L., Bottomley, M. J., Calzetta, A., Settembre, E. C., Cirillo, A., Pandit, S., Ni, Y. G., Hubbard, B. K., Sitlani, A., & Carfı́, A. (2011) · EMBO Reports · doi:10.1038/embor.2011.205 · Cited by 242 · see citing works
Self-citationThe Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232 · see citing works
Wu, Y., Carballo‐Jane, E., McLaren, D. G., Mendoza, V., Gagen, K., Geoghagen, N. S. M., McNamara, L. A., Gorski, J. N., Eiermann, G. J., Petrov, A., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m019927 · Cited by 220 · see citing works
Self-citationTargeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187 · see citing works
Chaparro‐Riggers, J. F., Hong, L., DeVay, R. M., Bai, L., Sutton, J. E., Chen, W., Geng, T., Lindquist, K. C., Casas, M. G., Boustany, L. M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.319764 · Cited by 166 · see citing works
Zhang, Y., Eigenbrot, C. W., Zhou, L., Shia, S., Li, W., Quan, C. L., Tom, J., Moran, P., Lello, P. D., Skelton, N. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.514067 · Cited by 158 · see citing works
Catapano, A. L., & Papadopoulos, N. J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.044 · Cited by 154 · see citing works
Lindholm, M., Elmén, J., Fisker, N., Hansen, H. F., Persson, R., Møller, M. R., Rosenbohm, C., Ørum, H., Straarup, E. M., & Koch, T. (2011) · Molecular Therapy · doi:10.1038/mt.2011.260 · Cited by 147 · see citing works
Ni, Y. G., Marco, S. D., Condra, J. H., Peterson, L. B., Wang, W., Wang, F., Pandit, S., Hammond, H. A., Rosa, R., Cummings, R. T., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m011445 · Cited by 135 · see citing works
Self-citationAnnexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
Seidah, N. G., Poirier, S., Denis, M., Parker, R. A., Miao, B., Mapelli, C., Prat, A., Wassef, H., Davignon, J., Hajjar, K. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041865 · Cited by 123 · see citing works
Seidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012989 · Cited by 119 · see citing works
Hirayama, A., Honarpour, N., Yoshida, M., Yamashita, S., Huang, F., Wasserman, S. M., & Teramoto, T. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0130 · Cited by 116 · see citing works
Kiyosue, A., Honarpour, N., Kurtz, C., Xue, A., Wasserman, S. M., & Hirayama, A. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.10.021 · Cited by 114 · see citing works
Mayne, J., Dewpura, T., Raymond, A., Bernier, L., Cousins, M., Ooi, T. C., Davignon, J., Seidah, N. G., Mbikay, M., & Chrétien, M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165191 · Cited by 111 · see citing works
Zhang, L., McCabe, T. J. D., Condra, J. H., Ni, Y. G., Peterson, L. B., Wang, W., Strack, A. M., Wang, F., Pandit, S., Hammond, H. A., et al. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.3524 · Cited by 101 · see citing works
Self-citationA Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
Yamamoto, T., Lu, C., & Ryan, R. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.199042 · Cited by 96 · see citing works
Lipari, M. T., Li, W., Moran, P., Kong-Beltran, M., Sai, T., Lai, J., Lin, S. J., Kolumam, G. A., Zavala‐Solorio, J., Izrael-Tomasevic, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.380618 · Cited by 93 · see citing works
Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
Glerup, S., Schulz, R., Laufs, U., & Schlüter, K. (2017) · Basic Research in Cardiology · doi:10.1007/s00395-017-0619-0 · Cited by 92 · see citing works
Sorting an LDL receptor with bound PCSK9 to intracellular degradation
Leren, T. P. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.08.038 · Cited by 92 · see citing works
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies
Seidah, N. G., Prat, A., Pirillo, A., Catapano, A. L., & Norata, G. D. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz003 · Cited by 89 · see citing works
Alvi, S. S., Ansari, I. A., Khan, I., Iqbal, J., & Khan, M. S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.012 · Cited by 88 · see citing works
Mayer, G., & Poirier, S. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s36984 · Cited by 83 · see citing works
Lammi, C., Zanoni, C., Aiello, G., Arnoldi, A., & Grazioso, G. (2016) · Scientific Reports · doi:10.1038/srep29931 · Cited by 84 · see citing works
Loss- and Gain-of-function PCSK9 Variants
Benjannet, S., Hamelin, J., Chrétien, M., & Seidah, N. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399725 · Cited by 83 · see citing works
Du, F., Hui, Y. Y., Zhang, M., Linton, M. F., Fazio, S., & Fan, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.273474 · Cited by 80 · see citing works
Ason, B. L., van der Hoorn, J. W. A., Chan, J. C. Y., Lee, E. W., Pieterman, E. J., Nguyen, K., Di, M., Shetterly, S., Tang, J. T., Yeh, W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m053207 · Cited by 80 · see citing works
Seidah, N. G. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100130 · Cited by 75 · see citing works
Konrad, R. J., Troutt, J. S., & Cao, G. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-38 · Cited by 72 · see citing works
Saavedra, Y. G. L., Day, R. W., & Seidah, N. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394023 · Cited by 69 · see citing works
Isolation and characterization of the circulating truncated form of PCSK9
Han, B., Eacho, P. I., Knierman, M. D., Troutt, J. S., Konrad, R. J., Yu, X., & Schroeder, K. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m049346 · Cited by 69 · see citing works
Kawakami, R., Nozato, Y., Hironori Nakagami, A., Ikeda, Y., Shimamura, M., Yoshida, S., Sun, J., Kawano, T., Takami, Y., Noma, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191895 · Cited by 68 · see citing works
DeVay, R. M., Shelton, D. L., & Liang, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.453373 · Cited by 66 · see citing works
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
Huijgen, R., Fouchier, S. W., Denoun, M., Hutten, B. A., Vissers, M. N., Lambert, G. C., & Kastelein, J. J. P. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p023994 · Cited by 67 · see citing works
PCSK9 targets important for lipid metabolism
Schulz, R., & Schlüter, K. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0085-0 · Cited by 64 · see citing works
Beyond LDL Cholesterol, a New Role for PCSK9
Akram, O. N., Bernier, A., Petrides, F., Wong, G., & Lambert, G. C. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.209007 · Cited by 59 · see citing works
Proprotein Convertase Subtilisin/Kexin 9 Inhibitors
Dragan, S. R., Șerban, M.-C., & Banach, M. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414539562 · Cited by 57 · see citing works
PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Banach, M., Rizzo, M., Obradovic, M. M., Montalto, G., Rysz, J., Mikhailidis, D. P., & Isenović, E. R. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990303 · Cited by 57 · see citing works
Guo, Y., Yan, B., Gui, Y., Tang, Z., Tai, S., Zhou, S., & Zheng, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30025 · Cited by 54 · see citing works
RETRACTED: Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial
Huijgen, R., Boekholdt, S. M., Arsenault, B. J., Bao, W., Davaine, J., Tabet, F., Petrides, F., Rye, K., DeMicco, D. A., Barter, P. J., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.043 · Cited by 54 · see citing works
RetractedPCSK9: an emerging target for treatment of hypercholesterolemia
Duff, C. J., & Hooper, N. M. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.547480 · Cited by 50 · see citing works
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9
Ason, B. L., Tep, S., Davis, J. H. R., Xu, Y., Tetzloff, G. G., Galinski, B., Soriano, F., Dubinina, N., Zhu, L., Stefanni, A. C., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m013664 · Cited by 49 · see citing works
Self-citationProprotein convertase subtilisin/kexin type 9 inhibition
Marais, D. A., Blom, D. J., Petrides, F., Gouëffic, Y., & Lambert, G. C. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283587563 · Cited by 48 · see citing works
Yadav, K., Sharma, M., & Ferdinand, K. C. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.05.006 · Cited by 47 · see citing works
Farnier, M. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283613a3d · Cited by 44 · see citing works
Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
Khoshnejad, M., Patel, A. R., Wojtak, K., Kudchodkar, S. B., Humeau, L. M. P. F., Lyssenko, N. N., Rader, D. J., Muthumani, K., & Weiner, D. B. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.016 · Cited by 39 · see citing works
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia
Verbeek, R., Stoekenbroek, R. M., & Hovingh, G. K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.099 · Cited by 37 · see citing works
Poirier, S., Hamouda, H. A., Villeneuve, L. R., Demers, A., & Mayer, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157230 · Cited by 34 · see citing works
Weider, E., Susan‐Resiga, D., Essalmani, R., Hamelin, J., Asselin, M.-C., Nimesh, S., Ashraf, Y., Wycoff, K. L., Zhang, J., Prat, A., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.717736 · Cited by 34 · see citing works
Mbikay, M., Mayne, J., & Chrétien, M. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12064 · Cited by 33 · see citing works
Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents
Abifadel, M., Pakradouni, J., Collin, M., Bouma, M. E., Varret, M., Rabès, J., & Boileau, C. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.518615 · Cited by 32 · see citing works
An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo
Schiele, F., Park, J. B., Redemann, N. H., Luippold, G., & Nar, H. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.11.011 · Cited by 32 · see citing works
Analytical Aspects of Proteomics: 2009–2010
Ning, Z., Zhou, H., Wang, F., Abu‐Farha, M., & Figeys, D. (2011) · Analytical Chemistry · doi:10.1021/ac200857t · Cited by 31 · see citing works
Altered islet prohormone processing: a cause or consequence of diabetes?
Ramzy, A., & Kieffer, T. J. (2021) · Physiological Reviews · doi:10.1152/physrev.00008.2021 · Cited by 27 · see citing works
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Hyperlipidemia
Farnier, M. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11590330-000000000-00000 · Cited by 28 · see citing works
Genome Editing for the Study of Cardiovascular Diseases
Chadwick, A. C., & Musunuru, K. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0830-5 · Cited by 26 · see citing works
Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody
Schroeder, K. M., Beyer, T. P., Hansen, R. J., Han, B., Pickard, R. T., Wroblewski, V. J., Kowala, M. C., & Eacho, P. I. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m061903 · Cited by 23 · see citing works
Proprotein Convertases and the Complement System
Dobó, J., Kocsis, A., Dani, R., & Gál, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958121 · Cited by 23 · see citing works
New Clinical Perspectives of Hypolipidemic Drug Therapy in Severe Hypercholesterolemia
Stefanutti, C., Morozzi, C., & Giacomo, S. D. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803341485 · Cited by 23 · see citing works
Novel therapeutic agents for lowering low density lipoprotein cholesterol
JOY, T. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.03.005 · Cited by 22 · see citing works
Koka, S., Xi, L., & Kukreja, R. C. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03710-0 · Cited by 22 · see citing works
Fruchart‐Gaillard, C., Ouadda, A. B. D., Ciccone, L., Girard, E., Mikaeeli, S., Evagelidis, A., Dévéhat, M. L., Susan‐Resiga, D., Lajeunesse, E. C., Nozach, H., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101662 · Cited by 22 · see citing works
Xu, M., Lei, G., Chen, M., Wang, K., Lv, W., Zhang, P., Hu, T., Gao, J., Lü, C., Mei, Y., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2021.103250 · Cited by 21 · see citing works
Jin, W., Yu, J., Su, Y., Lin, H., Liu, T., Chen, J., Ge, C., Zhao, F., Geng, Q., Mao, L., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81415 · Cited by 20 · see citing works
Guarnieri, F., Kulp, J. L., Kulp, J. L., & Cloudsdale, I. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225780 · Cited by 18 · see citing works
Ferri, N. (2012) · Scientifica · doi:10.6064/2012/927352 · Cited by 19 · see citing works
Shen, X., Wang, W., Wang, L., Houde, C., Wu, W., Tudor, M., Thompson, J. R., Sisk, C. M., Hubbard, B. K., & Li, J. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.012 · Cited by 18 · see citing works
Self-citationRhainds, D., Arsenault, B. J., & Tardif, J. (2012) · Clinical Lipidology · doi:10.2217/clp.12.74 · Cited by 18 · see citing works
DeVay, R. M., Yamamoto, L., Shelton, D. L., & Hong, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125127 · Cited by 16 · see citing works
Essalmani, R., Weider, E., Marcinkiewicz, J., Chamberland, A., Susan‐Resiga, D., Roubtsova, A., Seidah, N. G., & Prat, A. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0194 · Cited by 16 · see citing works
Ly, K., Essalmani, R., Desjardins, R., Seidah, N. G., & Day, R. W. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.746883 · Cited by 15 · see citing works
Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
Ouyang, M., Li, C., Hu, D., Peng, D., & Yu, B. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.11.018 · Cited by 13 · see citing works
Salim, H. M. W., Koire, A. M., Stover, N. A., & Cavalcanti, A. R. O. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-279 · Cited by 12 · see citing works
Povsic, T. J., Scott, R. C., Mahaffey, K. W., Blaustein, R. O., Edelberg, J. M., Lefkowitz, M. P., Solomon, S. D., Fox, J. C., Healy, K. E., Khakoo, A. Y., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6739-9 · Cited by 12 · see citing works
The Link between miRNAs and PCKS9 in Atherosclerosis
Mačvanin, M., Gluvic, Z. M., Klisic, A. N., Manojlovic, M. S., Suri, J. S., Rizzo, M., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673262124231102042914 · Cited by 11 · see citing works
Jha, M., Agrawal, S. P., Maheta, D., Bhattacharjee, P., Jain, H., Zacks, J. S., Frishman, W. H., & Aronow, W. S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2511063 · Cited by 10 · see citing works
Geschwindner, S., Andersson, G., Beisel, H., Breuer, S., Hallberg, C., Kihlberg, B., Lindqvist, A.-M., O’Mahony, G., Plowright, A. T., Raubacher, F., et al. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv008 · Cited by 9 · see citing works
Ultsch, M. H., Li, W., Eigenbrot, C. W., Lello, P. D., Lipari, M. T., Gerhardy, S., AhYoung, A. P., Quinn, J. G., Franke, Y., Chen, Y., et al. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.11.025 · Cited by 9 · see citing works
Update of Clinical Trials of Anti-PCSK9 Antibodies
Wu, N., Li, S., & Li, J. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6582-9 · Cited by 8 · see citing works
A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022
Luo, Q., Tang, Z., Wu, P., Chen, Z., Fang, Z., & Luo, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218968 · Cited by 9 · see citing works
Potential of PCSK9 as a new target for the management of LDL cholesterol
Mombelli, G. G., Pavanello, C., & Castelnuovo, S. (2015) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s52961 · Cited by 8 · see citing works
Gianazza, E., Macchi, C., Banfi, C., & Ruscica, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1191303 · Cited by 8 · see citing works
Mukhopadhyay, S., & Chakrabarty, S. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c05530 · Cited by 6 · see citing works
Vega, R. B., O’Mahony, G., Barbour, A., Yu, H., Knöchel, J., Brengdahl, J., Hochdörfer, T., Bergenholm, L., Carlsson, E. T., Ahnmark, A., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.075973 · Cited by 6 · see citing works
Self-citationBai, Z., Xu, M., Mei, Y., Hu, T., Zhang, P., Chen, M., Lv, W., Lü, C., & Tan, S. (2021) · Biomedicines · doi:10.3390/biomedicines9121783 · Cited by 6 · see citing works
Fazio, S., & Linton, M. F. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.034 · Cited by 5 · see citing works
Liu, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.150 · Cited by 4 · see citing works
VALIDATION OF PRECLINICAL PHARMACOKINETIC AND IMMUNOGENICITY ASSAYS FOR AN ANTI-PCSK9 ANTIBODY
Chilewski, S. D., Follmer, T. T., Ansbro, F., Chen, D., Zhao, Q., Teyral, J., Bakhtiar, R., & Verch, T. (2011) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2011.569046 · Cited by 4 · see citing works
Novel pharmacotherapies of familial hyperlipidemia
Drakopoulou, M. I., Toutouzas, K. P., & Stefanadis, C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.012 · Cited by 4 · see citing works
Identification and evaluation of a lipid-lowering small compound as a PCSK9 inhibitor
Xu, R., Wang, X., Gao, J., Li, Y., Wang, S., Li, H.-M., Sun, B., Dou, Z.-J., Hu, Y.-Y., Zhao, T., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.11.044 · Cited by 3 · see citing works
The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol
Blom, D. J., Marais, A. D., Raal, F. J., & Lambert, G. C. (2013) · Clinical Lipidology · doi:10.2217/clp.13.1 · Cited by 2 · see citing works
PCSK9 and lipid metabolism and atherosclerosis: animal models
Getz, G. S., & Reardon, C. A. (2021) · Vessel Plus · doi:10.20517/2574-1209.2020.70 · Cited by 2 · see citing works
Cao, G., Robert, J., Mark, C., & Wang, J. (2012) · InTech eBooks · doi:10.5772/29621 · Cited by 2 · see citing works
Cardiovascular complications of diabetes: recent insights in pathophysiology and therapeutics
Marette, A., & Sweeney, G. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.63 · Cited by 2 · see citing works
Seidah, N. G. (2012) · Handbook of Proteolytic Enzymes · doi:10.1016/b978-0-12-382219-2.00732-8 · Cited by 1 · see citing works
Studies on PCSK9 in the regulation of cholesterol metabolism
Persson, L. (2011) · Figshare · Cited by 1 · see citing works
- Authors
- Ni, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., Santoro, J. C., Ehrhardt, A., Lewis, D., Fisher, T. S., Ha, S., Njimoluh, L., Wood, D. D., Hammond, H. A., Wisniewski, D., Volpari, C., Noto, A., Lo Surdo, P., Hubbard, B., Carfí, A., & Sitlani, A.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Ni, Yan G.
- Sitlani, Ayesha
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 285
- Issue
- 17
- Pages
- 12882-12891
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC2857140
- OpenAlex
- W2062062360
- Cited by
- 107
- References
- 32
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 6 · 2015: 10 · 2014: 6 · 2013: 12 · 2012: 19
- FWCI
- 16.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9, C-terminal domain, Fab antibody, LDL receptor degradation, LDL uptake, hypercholesterolemia, phage display
- MeSH terms
- Proprotein Convertase 9, Antibodies, Monoclonal, Humans, Hypercholesterolemia, Immunoglobulin Fab Fragments, Lipoproteins, LDL, Receptors, LDL, Serine Endopeptidases, Mutagenesis, Site-Directed, Protein Structure, Secondary, Protein Structure, Tertiary, Amino Acid Substitution, Proprotein Convertases, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
